SLC34A1

If you keep forming kidney stones, your bones are thinning earlier than they should, or your child has nephrocalcinosis (calcium deposits in the kidney) with no clear cause, the answer may sit in a single gene. SLC34A1 (solute carrier family 34, member 1) builds a protein in your kidney that decides how much phosphate you keep versus lose in urine. When this gene carries certain variants, your kidneys leak phosphate, your active vitamin D rises, calcium spills into your urine, and stones, bone loss, and kidney damage can follow.

This test reads your SLC34A1 sequence to look for variants that explain (or predispose you to) those problems. It is not a blood chemistry that fluctuates day to day. It is a one-time look at the code you inherited, and a positive result reframes how your stone risk, bone density, and kidney function should be watched for the rest of your life.

What SLC34A1 Actually Does

SLC34A1 codes for NaPi-IIa (sodium-phosphate cotransporter 2a), a protein that sits on the surface of cells lining the proximal tubule, the part of your kidney that decides what to reabsorb from the filtered fluid before it becomes urine. NaPi-IIa is the main pump that pulls phosphate back into your bloodstream. Without enough functioning NaPi-IIa, phosphate leaks into the urine, your blood phosphate falls, and a chain of downstream effects begins.

Low phosphate signals your kidneys to make more active vitamin D, which then pulls more calcium out of your bones and food. The result is a familiar pattern on labs: low phosphate, high active vitamin D, suppressed PTH (parathyroid hormone), too much calcium spilling into urine, and often too much calcium in the blood. That biochemical pattern is the engine behind the stones, bone loss, and kidney calcifications seen in people carrying SLC34A1 variants.

Kidney Stones and Nephrocalcinosis

SLC34A1 variants are one of the more common monogenic drivers of kidney stones identified to date. In a Pakistani cohort of 235 families with nephrolithiasis (kidney stones), gene panel sequencing identified a likely single-gene cause in about 7%, and dominant SLC34A1 mutations were among the most frequent culprits. The variants identified showed defective phosphate uptake when tested in the lab.

In a deep biochemical phenotyping study of adult stone formers, rare variants in kidney stone genes including SLC34A1 carried real prognostic weight, with carriers showing higher recurrence over follow-up. Common SLC34A1 variants also show up in genome-wide association studies as one of the major loci tied to kidney stone risk in the general population, and Mendelian randomization analyses suggest that increasing serum phosphate through SLC34A1 pathways would reduce stone formation, meaning that lower-functioning variants push risk in the wrong direction.

In a separate cohort of carriers of pathogenic SLC34A1 and SLC34A3 variants, biallelic SLC34A1 carriers (two faulty copies) often presented in infancy with nephrocalcinosis, failure to thrive, and the hypercalcemic biochemistry described above. Heterozygous carriers (one faulty copy) tend to show milder, adult-onset disease centered on recurrent stones and lower bone density.

Infantile Hypercalcemia (IIH Type 2)

The most severe SLC34A1 phenotype is idiopathic infantile hypercalcemia type 2, caused by inheriting two loss-of-function copies. Babies present with hypercalcemia (high blood calcium), hypercalciuria (high urine calcium), nephrocalcinosis, failure to thrive, suppressed PTH, and elevated active vitamin D. Multiple case reports and cohort studies document this consistent pattern.

If you have a family history of infantile hypercalcemia, vitamin D hypersensitivity, or unexplained childhood nephrocalcinosis, knowing whether SLC34A1 is involved changes how future pregnancies, siblings, and offspring should be evaluated. Carrier testing is especially relevant when one partner is known to carry a pathogenic variant.

Bone Loss and Early Osteoporosis

Because SLC34A1 variants drive phosphate wasting and shift calcium out of bone, carriers can show unusually early osteopenia or osteoporosis. The condition called NPHLOP1 (hypophosphatemic nephrolithiasis with osteoporosis type 1) links heterozygous SLC34A1 mutations to both recurrent stones and low bone density. A case report described a young man with a novel SLC34A1 variant presenting with recurrent stones and osteopenia well before the age it would normally be expected.

If your DEXA scan shows bone loss that does not fit your age or risk profile, and you also have a history of stones or hypercalciuria, an SLC34A1 finding can connect those dots into a single diagnosis.

Chronic Kidney Disease Risk

Long-term, repeated calcium deposition in the kidneys can erode filtration. A cohort study of SLC34A1 and SLC34A3 carriers found increased prevalence of chronic kidney disease in adulthood compared with the general population, with SLC34A3 carriers showing a markedly higher CKD risk and SLC34A1 carriers showing meaningful but distinct kidney consequences. A large genetic study identified common SLC34A1 variants as part of the genetic architecture of kidney function and CKD susceptibility in the broader population. Severe cases have also been linked to renal Fanconi syndrome, where the proximal tubule loses its general ability to reabsorb nutrients.

Why a Single Reading Is Enough, But Follow-Up Testing Is Not Optional

Unlike blood markers that move with diet, stress, or sleep, your SLC34A1 genotype does not change. A single high-quality sequence is your answer. What does need ongoing tracking is the downstream biology this gene controls: blood phosphate, calcium, active vitamin D, PTH, urinary calcium and phosphate, kidney imaging, and bone density. If you carry a pathogenic SLC34A1 variant, those follow-up labs and scans need to be checked at baseline and rechecked at least yearly, because the disease expression is variable and can change with age, pregnancy, vitamin D exposure, and kidney function.

Children identified with biallelic variants often improve clinically with hydration, dietary adjustments, and supportive management, and many adults stabilize with the right monitoring. The point of the genetic test is not to predict your future precisely; it is to know whether you belong in the group that needs structured surveillance.

What to Do With an Abnormal Result

A positive SLC34A1 result is a starting point for a workup, not the end of one. The combinations of findings that warrant action are usually clear: an SLC34A1 variant plus low blood phosphate, high active vitamin D, suppressed PTH, hypercalciuria, or nephrocalcinosis on imaging tells a coherent story and should trigger management.

• Companion labs to order: phosphate, calcium (total and ionized), PTH, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, FGF-23, alkaline phosphatase, and a comprehensive metabolic panel. A 24-hour urine collection for calcium, phosphate, and creatinine confirms renal phosphate wasting and hypercalciuria.
• Imaging and structural assessment: renal ultrasound to look for nephrocalcinosis or stones, and a DEXA scan to assess bone density, particularly if you have any stone or fracture history.
• Specialists worth involving: a nephrologist if you have stones, nephrocalcinosis, or any reduction in kidney function, and an endocrinologist if the calcium-phosphate-vitamin D picture is abnormal or if bone density is low.
• Family screening: parents, siblings, and children of someone with a confirmed pathogenic variant should be considered for testing, because the same variant can present very differently across a family.

If your SLC34A1 result is normal but you have unexplained stones, hypercalcemia, or low phosphate, the workup does not stop. Overlapping phenotypes between SLC34A1, SLC34A3 (the related transporter NaPi-IIc), and CYP24A1 (a vitamin D-degrading enzyme) mean that a broader genetic panel is often the next step. In a cohort of patients with vitamin D hypersensitivity, no single biochemical pattern reliably picked out which gene was involved, so panel sequencing is usually the right move.

Reconciling the Carrier State Question

You may read that heterozygous SLC34A1 variants are clearly disease-causing in one paper and questionable in another. Both can be right. Heterozygous carriers can show milder biochemical changes and increased stone risk, but penetrance is variable. Some carriers form stones in their twenties; others go their whole lives without symptoms. This is not a contradiction in the science; it is a feature of the gene. A heterozygous result tells you that you carry meaningful risk, but it does not predict the severity of your individual disease. That is why pairing the genetic result with the metabolic workup matters so much.

What This Test Does Not Do

This is a focused genetic test of a single gene known to drive a specific set of phosphate-handling disorders. It does not screen for all causes of kidney stones, all forms of hereditary kidney disease, or all causes of osteoporosis. A negative result rules out SLC34A1 as the explanation but does not rule out other monogenic stone genes, dietary causes, hyperparathyroidism, or common metabolic stone disease. Standard biochemistry panels do not include SLC34A1, and routine kidney function tests will not flag it unless damage has already occurred, which is the reason proactive testing in the right person is worthwhile.